Atlas Trials

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Clinical trial NCT02603107 · COMPLETED

Trial details

NCT number
NCT02603107
Sponsor
Gilead Sciences
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
HIV-1 Infection
Start date
2015-11-20
Primary completion
2017-05-15
Enrollment
578

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.